ReviewBiochimica et biophysica acta. Reviews on cancer2026
The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies.
Review in Biochimica et biophysica acta. Reviews on cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.International journal of molecular sciences · 2026Article
- Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 has revolutionized the treatment of B-cell malignancies. One of the critical factors influencing CAR-T efficacy and durability is the costimulatory domain, with 4-1BB and CD28 emerging as the two dominant signaling platforms. While CD28-based CAR-T cells exhibit strong initial potency and rapid expansion, 4-1BB-based CAR-T cells demonstrate greater persistence and long-term efficacy. However, resistance to CAR-T therapy remains a significant challenge. Tumor cells develop a variety of mechanisms to evade immune surveillance, including CD19 antigen escape due to epigenetic factors or genetic aberrations of the CD19 gene. This review article summarizes the mechanistic differences between both costimulatory domains, their impact on clinical outcomes, and how they might influence resistance occurrence. By dissecting the battle of potency and the race of persistence, we provide insights into the evolving landscape of CAR-T therapy for B-cell malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.